Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Role of kappa-opioid receptors in stress and anxiety-related behavior.

Van't Veer A, Carlezon WA Jr.

Psychopharmacology (Berl). 2013 Oct;229(3):435-52. doi: 10.1007/s00213-013-3195-5. Epub 2013 Jul 9. Review.

2.

Dynorphin, stress, and depression.

Knoll AT, Carlezon WA Jr.

Brain Res. 2010 Feb 16;1314:56-73. doi: 10.1016/j.brainres.2009.09.074. Epub 2009 Sep 24. Review.

3.
4.

CRF1-R activation of the dynorphin/kappa opioid system in the mouse basolateral amygdala mediates anxiety-like behavior.

Bruchas MR, Land BB, Lemos JC, Chavkin C.

PLoS One. 2009 Dec 31;4(12):e8528. doi: 10.1371/journal.pone.0008528.

5.

Effects of acute and chronic social defeat stress are differentially mediated by the dynorphin/kappa-opioid receptor system.

Donahue RJ, Landino SM, Golden SA, Carroll FI, Russo SJ, Carlezon WA Jr.

Behav Pharmacol. 2015 Oct;26(7 Spec No):654-63. doi: 10.1097/FBP.0000000000000155.

PMID:
26110224
6.

Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment.

Crowley NA, Kash TL.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Oct 1;62:51-60. doi: 10.1016/j.pnpbp.2015.01.001. Epub 2015 Jan 12. Review.

PMID:
25592680
7.

The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors.

Bruchas MR, Land BB, Chavkin C.

Brain Res. 2010 Feb 16;1314:44-55. doi: 10.1016/j.brainres.2009.08.062. Epub 2009 Aug 28. Review.

8.

Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats.

Knoll AT, Meloni EG, Thomas JB, Carroll FI, Carlezon WA Jr.

J Pharmacol Exp Ther. 2007 Dec;323(3):838-45. Epub 2007 Sep 6.

9.

Protracted withdrawal from ethanol and enhanced responsiveness stress: regulation via the dynorphin/kappa opioid receptor system.

Gillett K, Harshberger E, Valdez GR.

Alcohol. 2013 Aug;47(5):359-65. doi: 10.1016/j.alcohol.2013.05.001. Epub 2013 May 31.

10.

Activation of κ opioid receptors increases intrinsic excitability of dentate gyrus granule cells.

McDermott CM, Schrader LA.

J Physiol. 2011 Jul 15;589(Pt 14):3517-32. doi: 10.1113/jphysiol.2011.211623. Epub 2011 May 23.

11.

Ablation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticity.

Van't Veer A, Bechtholt AJ, Onvani S, Potter D, Wang Y, Liu-Chen LY, Schütz G, Chartoff EH, Rudolph U, Cohen BM, Carlezon WA Jr.

Neuropsychopharmacology. 2013 Jul;38(8):1585-97. doi: 10.1038/npp.2013.58. Epub 2013 Feb 27.

12.

Comparison of the kappa-opioid receptor antagonist DIPPA in tests of anxiety-like behavior between Wistar Kyoto and Sprague Dawley rats.

Carr GV, Lucki I.

Psychopharmacology (Berl). 2010 Jun;210(2):295-302. doi: 10.1007/s00213-010-1832-9. Epub 2010 Apr 6.

13.

Stress-induced activation of the dynorphin/κ-opioid receptor system in the amygdala potentiates nicotine conditioned place preference.

Smith JS, Schindler AG, Martinelli E, Gustin RM, Bruchas MR, Chavkin C.

J Neurosci. 2012 Jan 25;32(4):1488-95. doi: 10.1523/JNEUROSCI.2980-11.2012.

14.

Big dynorphin as a putative endogenous ligand for the kappa-opioid receptor.

Merg F, Filliol D, Usynin I, Bazov I, Bark N, Hurd YL, Yakovleva T, Kieffer BL, Bakalkin G.

J Neurochem. 2006 Apr;97(1):292-301. Epub 2006 Mar 3.

15.

Development of κ opioid receptor antagonists.

Carroll FI, Carlezon WA Jr.

J Med Chem. 2013 Mar 28;56(6):2178-95. doi: 10.1021/jm301783x. Epub 2013 Feb 14. Review.

16.

Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models.

Kehne JH, Cain CK.

Pharmacol Ther. 2010 Dec;128(3):460-87. doi: 10.1016/j.pharmthera.2010.08.011. Epub 2010 Sep 6. Review.

17.

Corticotropin-releasing factor (CRF)-induced disruption of attention in rats is blocked by the κ-opioid receptor antagonist JDTic.

Van't Veer A, Yano JM, Carroll FI, Cohen BM, Carlezon WA Jr.

Neuropsychopharmacology. 2012 Dec;37(13):2809-16. doi: 10.1038/npp.2012.151. Epub 2012 Sep 5.

18.

The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders.

Kehne JH.

CNS Neurol Disord Drug Targets. 2007 Jun;6(3):163-82. Review.

PMID:
17511614
19.

Interaction of CRF and kappa opioid systems on GABAergic neurotransmission in the mouse central amygdala.

Kang-Park M, Kieffer BL, Roberts AJ, Siggins GR, Moore SD.

J Pharmacol Exp Ther. 2015 Nov;355(2):206-11. doi: 10.1124/jpet.115.225870. Epub 2015 Sep 8.

PMID:
26350161
20.

Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.

Grimwood S, Lu Y, Schmidt AW, Vanase-Frawley MA, Sawant-Basak A, Miller E, McLean S, Freeman J, Wong S, McLaughlin JP, Verhoest PR.

J Pharmacol Exp Ther. 2011 Nov;339(2):555-66. doi: 10.1124/jpet.111.185108. Epub 2011 Aug 5.

Items per page

Supplemental Content

Write to the Help Desk